Ursodeoxycholic Acid (UDCA) is Not Recommended for Hepatic Steatosis
Evidence Against UDCA Use in Hepatic Steatosis
- The American Association for the Study of Liver Diseases (AASLD) explicitly states that UDCA is not recommended for the treatment of NAFLD or NASH (Strength - 1, Quality - B) 1, 2
- A large multicenter randomized controlled trial convincingly demonstrated that UDCA offers no histological benefit over placebo in patients with NASH 1
- Most studies investigating UDCA for hepatic steatosis have been small proof-of-concept studies with limited participants and/or surrogate endpoints, failing to show meaningful clinical benefits 2
Alternative First-Line Treatments for Hepatic Steatosis
- For non-diabetic adults with biopsy-proven NASH, vitamin E (α-tocopherol) at 800 IU/day is recommended as first-line pharmacotherapy as it improves liver histology 1, 2
- Lifestyle modifications including weight loss through diet and exercise remain the cornerstone of NAFLD management 1
- For patients with NAFLD and hypertriglyceridemia, omega-3 fatty acids may be considered as first-line agents for treating the lipid abnormality, though they are not specifically recommended for treating the underlying liver disease 2
Potential Harm of UDCA in Liver Disease
- In primary sclerosing cholangitis (PSC), high-dose UDCA (28-30 mg/kg/day) has been associated with higher rates of serious adverse events and worse outcomes including death, liver transplantation, and development of varices 3, 4, 5
- The British Society of Gastroenterology strongly recommends against routine use of UDCA for newly diagnosed PSC due to limited efficacy and potential harm 3, 5
Mechanism of Action and Limited Benefits
- While UDCA may improve liver biochemistry in various liver diseases, this biochemical improvement does not translate to improved clinical outcomes in hepatic steatosis 3
- Larger trials with UDCA alone have not confirmed benefits in human clinical trials 1, 2